Please Wait.....
Report
Theranostics: Global Markets
Market Research Report I 2024-08-05 I 118 Pages I BCC Research
Description
Report Scope:
This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.
Report Includes:
-45 data tables and 37 additional tables
- An overview of the global markets for theranostics
- Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
- Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
- Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
- Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services
- Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
- A discussion of ESG challenges and ESG practices in the industry
- Analysis of the key companies' market shares, proprietary technologies and strategic alliances
- Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.
Executive Summary
Summary:
Theranostics is a combination of therapeutics and diagnostics. The main aim of theranostics is to provide diagnostics and therapeutics together in order to personalize treatment. The term was first coined by John Funkhouser in 1998. Theranostics is a prime example of personalized medicine. Radiotheranostics are applied via radionuclides, as they have properties for diagnosis and therapeutics. The primary application of theranostics is in the field of oncology.
The theranostics market is relatively new, being only about two decades old. A significant driver for theranostics is the inherent disadvantages of conventional cancer treatment. Chemotherapy has been the most widely used form of cancer treatment and is the first line of treatment for many cancers. However, chemotherapy has many disadvantages, such as adverse effects on healthy cells, loss of effectiveness on cancer cells and lack of a way to provide personalized treatment. With the help of theranostics, customized treatment can be provided to the patient, which helps overcome chemotherapy's limitations and side effects.
One of the major factors driving the theranostics market is the rising number of cancer cases in both developed and developing countries. Cancer cases are on the rise in developed countries due to the population aging and earlier and more effective screening. In contrast, cancer cases are increasing in developing countries due to growth in overall population and changing lifestyles. On the other hand, the cancer mortality rates have been declining in many regions and countries. The declining mortality rates are due to advancements in cancer treatment and early detection. Nonetheless, the rising number of cancer patients will lead to a demand for new and better technology that effectively treats the disease and improves patients' quality of life. This is possible through theranostics.
The market is faced with challenges and restraints that are holding the market back. One of the significant challenges of theranostics is the cost of treatment. Theranostics employs high-end equipment and reagents. Compared to other cancer treatments, the cost of theranostics procedures can be very high due to the involvement of many experts. It is one of the significant reasons for slow adoption, particularly in cost-sensitive markets.
Another challenge is the failure of some early radiotherapeutics. The current theranostics market is based on radionuclides. Commercial failure of these drugs has significantly hindered the market's growth. Investors may be hesitant due to a lack of return on investments.
The major opportunity in the market is for treating cancer, particularly prostate cancer and neuroendocrine tumors. Theranostics can also be applied to other cancers. Radionuclides are conjugated with antibodies, proteins and other biomarkers to achieve targeted radionuclide therapy.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
PESTLE Analysis
Political
Economic
Social
Technological
Legal
Environmental
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Competition in the Industry
Threat of Substitutes
R&D and Regulatory Approval
The Drug Development Process
Drug Discovery
Preclinical Development
Clinical Trials
The New Drug Application Review
NDA Data Review
Clinical Trials for Theranostics
Steps Followed for Radiotherapeutics in Clinical Trials
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Theranostics Replacing Conventional Treatment
Increased Application of Theranostics in Drug Discovery
Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
New Radiotheranostics Driving the Theranostics Market
Rise in Chronic Inflammatory Diseases
Cancer Epidemics in Developing Countries
Market Restraints
High Cost of Theranostics
Market Challenges
Nanotheranostics-Bio Interactions
Challenges of Radiotheranostics
Failure of Radiotherapeutics
Market Opportunities
Theranostics in Cardiovascular Diseases
Chapter 4 Emerging Technologies and Developments
Artificial Intelligence in Theranostics
Drug Delivery Using Innovative Material
Boron Neutron Capture Therapy (BNCT)
Luminogen Aggregation-Induced Emission (AIE)
Theranostics in Rheumatoid Arthritis (RA)
Chapter 5 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis, by Product Type
Theranostics Equipment
Theranostics Agents
Diagnostics Theranostics Agents
Therapeutics Theranostics Agents
Market Analysis, by Application
Etiology of Cancer
Cancer Diagnosis
Cancer Therapeutics
Prostate Cancer
Neuroendocrine Tumors
Thyroid Cancer
Neuroblastoma
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Competitive Intelligence
Strategic Analysis
Clinical Trials Analysis
Chapter 7 Sustainability in Theranostics Market: An ESG Perspective
Introduction to ESG
Key ESG Issues in the Theranostics Market
Safety of Personnel
Disposal of Radioactive Waste
Nanopollution
Current Status of ESG in the Theranostics Market
ESG Performance Analysis
Concluding Remark from BCC Research
Chapter 8 Appendix
Methodology
Sources
Acronyms
Company Profiles
BAYER AG
CURIUM PHARMA
GE HEALTHCARE
LANTHEUS
NOVARTIS AG
SIEMENS HEALTHINEERS AG
TELIX PHARMACEUTICALS LTD.
Other Companies
List of Tables
Summary Table : Global Market for Theranostics, by Product Type, Through 2029
Table 1 : Approved Radiopharmaceuticals for Radiotheranostics, 2024
Table 2 : Worldwide Regulatory Authorities, 2024
Table 3 : Dosimetry Pre-therapy and Post-therapy
Table 4 : Global Market for Theranostics, by Product Type, Through 2029
Table 5 : Global Market for Theranostics Equipment, by Type, Through 2029
Table 6 : Global Market for Theranostics Equipment, by Region, Through 2029
Table 7 : Global Market for PET Theranostics Equipment, by Region, Through 2029
Table 8 : Global Market for SPECT Theranostics Equipment, by Region, Through 2029
Table 9 : Global Market for MRI Theranostics Equipment, by Region, Through 2029
Table 10 : Global Market for Other Theranostics Equipment, by Region, Through 2029
Table 11 : Global Market for Theranostics Agents, by Type, Through 2029
Table 12 : Global Market for Theranostics Agents, by Region, Through 2029
Table 13 : Select Theranostics Pair
Table 14 : Properties of Commonly Used Radionuclides in Theranostics
Table 15 : Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
Table 16 : Difference Between Alpha Particles and Beta Particles
Table 17 : Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
Table 18 : Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
Table 19 : Advantages and Disadvantages of Various Cancer Treatments
Table 20 : Global Market for Theranostics Applications, by Type, Through 2029
Table 21 : Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
Table 22 : Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
Table 23 : Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
Table 24 : Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
Table 25 : Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
Table 26 : Estimated Number of Cancer Deaths Per Region, 2022 and 2045
Table 27 : North American Market for Theranostics, by Product Type, Through 2029
Table 28 : North American Market for Theranostics Equipment, by Type, Through 2029
Table 29 : North American Market for Theranostics Agents, by Type, Through 2029
Table 30 : North American Market for Theranostics Applications, by Type, Through 2029
Table 31 : North American Market for Theranostics, by Country, Through 2029
Table 32 : Theranostics Centers Needed in the U.S.
Table 33 : European Market for Theranostics, by Product Type, Through 2029
Table 34 : European Market for Theranostics Equipment, by Type, Through 2029
Table 35 : European Market for Theranostics Agents, by Type, Through 2029
Table 36 : European Market for Theranostics Applications, by Type, Through 2029
Table 37 : European Market for Theranostics, by Country, Through 2029
Table 38 : Asia-Pacific Market for Theranostics, by Product Type, Through 2029
Table 39 : Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
Table 40 : Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
Table 41 : Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
Table 42 : Asia-Pacific Market for Theranostics, by Country, Through 2029
Table 43 : Rest of the World Market for Theranostics, by Product Type, Through 2029
Table 44 : Rest of the World Market for Theranostics Equipment, by Type, Through 2029
Table 45 : Rest of the World Market for Theranostics Agents, by Type, Through 2029
Table 46 : Rest of the World Market for Theranostics Applications, by Type, Through 2029
Table 47 : Market Ranking, Theranostics Agents
Table 48 : Strategic Analysis: Theranostics Market, 2021-2024
Table 49 : Targeted Radioligands Therapy in Clinical Trials, 2024
Table 50 : The Three Pillars of ESG
Table 51 : ESG Ranking of Leading Theranostics Players
Table 52 : ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
Table 53 : Report Information Sources
Table 54 : Major Acronyms Used in the Global Theranostics Market
Table 55 : Bayer AG: Company Snapshot
Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 57 : Bayer AG: Product Portfolio
Table 58 : Bayer AG: News/Key Developments, 2021-2023
Table 59 : Curium Pharma: Company Snapshot
Table 60 : Curium Pharma: Product Portfolio
Table 61 : GE Healthcare: Company Snapshot
Table 62 : GE Healthcare: Financial Performance, FY 2022 and 2023
Table 63 : GE Healthcare: Product Portfolio
Table 64 : GE Healthcare: News/Key Developments, 2023-2024
Table 65 : Lantheus: Company Snapshot
Table 66 : Lantheus: Financial Performance, FY 2022 and 2023
Table 67 : Lantheus: Product Portfolio
Table 68 : Lantheus: News/Key Developments, 2023-2024
Table 69 : Novartis AG: Company Snapshot
Table 70 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 71 : Novartis AG: Product Portfolio
Table 72 : Novartis AG: News/Key Developments, 2022
Table 73 : Siemens Healthineers AG: Company Snapshot
Table 74 : Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 75 : Siemens Healthineers AG: Product Portfolio
Table 76 : Siemens Healthineers AG: News/Key Developments, 2022
Table 77 : Telix Pharmaceutical Ltd.: Company Snapshot
Table 78 : Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
Table 79 : Telix Pharmaceutical Ltd.: Product Portfolio
Table 80 : Telix Pharmaceutical Ltd.: News/Key Developments, 2022-2024
Table 81 : Upcoming Startups in The Field of Theranostics
List of Figures
Summary Figure : Global Market for Theranostics, by Product Type, 2021-2029
Figure 1 : Theranostics Workflow
Figure 2 : Components of the Drug Approval Process
Figure 3 : Preclinical and Clinical Trials Phases
Figure 4 : Clinical Trials Radionuclide Pictorial Representative, 2024
Figure 5 : Market Dynamics of Theranostics
Figure 6 : Disadvantages of Chemotherapy Treatment
Figure 7 : Drug Development Cost, 2002 and 2022
Figure 8 : Global Market Shares of Theranostics, by Product Type, 2023
Figure 9 : Global Market Shares of Theranostics, by Product Type, 2029
Figure 10 : Global Market Shares of Theranostics Equipment, by Type, 2023
Figure 11 : Global Market Shares of Theranostics Agents, by Type, 2023
Figure 12 : Schematic Representation of Radionuclide Therapy
Figure 13 : Schematic Representation of Radionuclide Therapy
Figure 14 : Etiology of Cancer
Figure 15 : Cancer Diagnostics Methods
Figure 16 : Types of Imaging
Figure 17 : Asia-Pacific Cancer Incidence, 2008 and 2030
Figure 18 : Global Market Shares of Theranostics Instruments, by Installation Base, 2024
Figure 19 : Share of Clinical Trials, by Recruiting Status, 2024
Figure 20 : Share of Clinical Trials, by Type of Indication, 2024
Figure 21 : Share of Clinical Trials, by Phase, 2024
Figure 22 : Share of Clinical Trials, by Type of Funder, 2024
Figure 23 : Share of Clinical Trials, by Gender, 2024
Figure 24 : The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
Figure 25 : ESG Concerns in the Theranostics Market
Figure 26 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 27 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 28 : GE Healthcare: Revenue Share, by Business Unit, FY 2023
Figure 29 : GE Healthcare: Revenue Share, by Country/Region, FY 2023
Figure 30 : Lantheus: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 34 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 35 : Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security